Form 8-K - Current report:
SEC Accession No. 0001628280-23-006049
Filing Date
2023-03-02
Accepted
2023-03-02 16:14:01
Documents
15
Period of Report
2023-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20230302.htm   iXBRL 8-K 39135
2 EX-99.1 crdf3222-q42022pr.htm EX-99.1 117570
6 crdf-20230302_g1.jpg GRAPHIC 2732
7 image_0.jpg GRAPHIC 17916
  Complete submission text file 0001628280-23-006049.txt   332782

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20230302.xsd EX-101.SCH 1923
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20230302_lab.xml EX-101.LAB 22875
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20230302_pre.xml EX-101.PRE 11999
9 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20230302_htm.xml XML 10063
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 23699083
SIC: 2836 Biological Products, (No Diagnostic Substances)